Table 3.
Summary of responses to kisspeptin 112 to 121 (0.24 nmol/kg)
| Pulse frequency, pulses | LH pulse amplitude, mIU/mL | Mean LH, mIU/mL | IPI, h | FSH across visitsb, mIU/mL | FSH first kisspeptin administrationc, mIU/mL | Estradiol, pg/mLd | Estradiol after DA washout, pg/mL | |
|---|---|---|---|---|---|---|---|---|
| Visit 1 mean | 4.5 ± 0.9 | 4.60 ± 2.03 | 3.32 ± 0.60 | 2.7 ± 0.5 | 4.6 ± 1.0 | 4.6 ± 1.0 | 48.8 ± 8.2 | 54.1 ± 9.5 |
| Visit 2 mean | 7.5 ± 0.5 | 3.11 ± 0.84a | 5.91 ± 0.65 | 1.3 ± 0.1 | 5.2 ± 0.9 | 4.6 ± 0.9 | 54.2 ± 9.1 | 53.7 ± 11.4 |
Summary of mean values for characteristics used to assess response to kisspeptin administration (hour 1-hour 11).
Abbreviations: DA, dopamine agonist; FSH, follicle-stimulating hormone; IPI, interpulse interval; LH, luteinizing hormone.
a Pulse amplitude value for Visit 2 only includes pulse amplitude value following first kisspeptin bolus.
b Visit 1 mean includes values across all baseline sampling time frame (hour 0—hour 12).
c Visit 1 mean includes values across all baseline sampling timepoints. Visit 2 includes values collected during the first 2 hours after kisspeptin administration.
d This column includes the entire cohort (n = 11). Visit 1 mean includes values across all baseline sampling time frame (hour 0-hour 12).
e This column includes individuals who underwent DA washout (n = 7). Visit 1 mean includes values across all baseline sampling time frame.